Trial Profile
Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Iopofosine I 131 (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Proof of concept
- Sponsors Cellectar Biosciences
- 21 Feb 2023 Status changed from active, no longer recruiting to completed.
- 18 Jul 2022 Planned End Date changed from 15 Apr 2020 to 1 Aug 2022.
- 18 Jul 2022 Status changed from completed to active, no longer recruiting.